Bradanicline

N/A

Report date: 2024/05/22 20:00:38
NME

Base Information

Drug NameBradanicline
Drug Alias NameBradaniclinum布瑞克兰Bradaniclina布达克兰TC-0569 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuronal acetylcholine receptor protein alpha-7 subunit agonists
TargetsNeuronal acetylcholine receptor protein alpha-7 subunit
Therapy Area/IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityCognitive Dysfunction +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineRomania +[7] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTargacept Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAttenua IncTargacept Inc
Active IndicationsN/A
Inactive IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityCognitive Dysfunction +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG